Pharmaceutical News

RSS

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Researchers find influenza vaccines can contain allergenic components

People with egg or gelatin allergies shouldn't assume that just because they've had a flu shot safely in the past they will be able to again, according to a new study, presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16.

15 Nov 2010

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients.

15 Nov 2010

AMP receives FDA approval to manufacture ophthalmic product using Capmatic Patriot dropper bottle filling line

Alliance Medical Products announced today, at the AAPS Annual Meeting and Exposition, the U.S. Food and Drug Administration (FDA) has granted approval to manufacture a certain commercially available ophthalmic product using the company's high speed dropper bottle filling line.

15 Nov 2010

Study finds children more likely to be allergic to amoxicillin

Children are more likely to have an allergy to amoxicillin than adults, according to a study presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16. Amoxicillin is a form of penicillin.

15 Nov 2010

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

The Bill & Melinda Gates Foundation has awarded nationally prominent Oregon Health & Science University reproductive scientist Jeffrey T. Jensen, M.D., M.P.H., a $100,000 grant to investigate the safety and effectiveness of a novel low-cost family-planning option that may be applicable to women in low-resource countries worldwide.

15 Nov 2010

Report documents increase in R&D projects on developing world diseases

Drugmakers are now working on over 100 R&D projects designed to tackle diseases of the developing world and almost 80% of them are being carried out with non-industry partners, according to a report released on Wednesday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

15 Nov 2010

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

There is a simple explanation for most of the mergers and acquisitions in the pharmaceutical world these days the so called Patent Cliff. Simply put, many of the drug industry's biggest earners blockbuster medications that have paid the bills for the last decade are about to lose their patent protections.

15 Nov 2010

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

15 Nov 2010

Acne, acne medicine and mental health: Study

Acne drug Accutane (isotretinoin) has been plagued by serious controversies with some linking it to suicidal tendencies. Now the latest research finds that severe acne itself increases the risk for suicidal thoughts and actions, raising more questions about the role of the drug, if any, in suicide.

14 Nov 2010

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

12 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

Dreaded cod liver oil in a variety of flavours

The stomachs of the generation of 50 year olds and above, will be churning at the thought of their parents and grandparents serving up spoonfuls of the much dreaded cod liver oil. As a practice, parents giving their children cod liver oil has all but died, and yet, as a population, we have seen more and more inflammatory conditions effect people's lives, which are due in no small part to the 'modern day diet', which many of us live.

12 Nov 2010

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.

12 Nov 2010

Urgent action needed to prevent and treat childhood pneumonia

A Pneumonia Report Card released today by the International Vaccine Access Center (IVAC) on behalf of the Global Coalition against Child Pneumonia reveals where urgent efforts are needed to reach target levels of coverage for the life-saving interventions that can prevent, protect against and treat pneumonia in children.

12 Nov 2010

Ordway, Milestone to develop drug formulation for administration through CompuFlo injection technology

Milestone Scientific Inc., the recognized leader in advanced, computer controlled drug delivery technologies, and Ordway Research Institute, a leading research and drug development organization, have agreed to develop drug formulations for precise targeted delivery of drugs to affected body parts, organs and cancerous tissue through Milestone's patented CompuFlo injection technology.

12 Nov 2010

Carter Center, Merck take steps to prevent river blindness in Latin America

Public health officials at the 20th Inter-American Conference on Onchocerciasis in Antigua, Guatemala, confirmed that more than one-third of all Latin Americans who ran the risk of contracting river blindness (onchocerciasis), a leading cause of preventable blindness, are no longer at risk.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Pharmaceutical News

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Researchers find influenza vaccines can contain allergenic components

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

AMP receives FDA approval to manufacture ophthalmic product using Capmatic Patriot dropper bottle filling line

Study finds children more likely to be allergic to amoxicillin

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

Report documents increase in R&D projects on developing world diseases

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

Labopharm receives notice about Activis' ANDA for OLEPTRO

Acne, acne medicine and mental health: Study

Neurologix third quarter net loss decreases to $2.3 million

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

VIMOVO granted marketing and pricing approval in the UK

Dreaded cod liver oil in a variety of flavours

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

Urgent action needed to prevent and treat childhood pneumonia

Ordway, Milestone to develop drug formulation for administration through CompuFlo injection technology

Carter Center, Merck take steps to prevent river blindness in Latin America

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News